RESUMO
Explanted cultures of crystalline lenses have been used to investigate mechanisms of xenobiotic-induced cataract formation. However, very few studies have utilized mechanistic information to predict the cataractogenic potential of structurally diverse xenobiotics. The present investigation outlines how visual assessment of lens clarity, biochemical endpoints of toxicity, and mechanisms of lenticular opacity formation can be used to select compounds with a lower probability of causing cataract formation in vivo. The rat lens explant culture system has been used to screen thiazolidinediones against ciglitazone for their direct cataractogenic potential in vitro. The two compounds that were selected as development candidates (englitazone and darglitazone) did not produce cataracts in rats exposed daily for 3 months. The culture system has also been used to illustrate that the lens is capable of metabolizing compounds to reactive intermediates. In this example, the toxicity of S-(1,2-dichlorovinyl)-L-cysteine (DCVC), a model cataractogen, was attenuated by inhibiting lenticular cysteine conjugate beta-lyase metabolism using aminooxyacetic acid. Finally, this model was used retrospectively to investigate the cataractogenic potential of CJ-12,918 and CJ-13,454 in rats. These compounds showed differences in the incidence of cataract formation in vivo based on differences in hepatic metabolism and penetration of parent drug and metabolites into the lens. The rank order of cataractogenic potential in vitro correlated better with in vivo results when an induced S9 microsomal fraction was added to the culture media. However, the model did not correctly predict the cataractogenic potential of ZD2138, a structurally similar compound. These studies illustrate the use of explant culture to assess mechanisms of cataract formation and outline its use and limitations for predicting cataractogenic potential in vivo.
Assuntos
Catarata/induzido quimicamente , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/patologia , Cristalino/patologia , Tiazolidinedionas , Testes de Toxicidade/métodos , Trifosfato de Adenosina/metabolismo , Ácido Amino-Oxiacético/farmacologia , Animais , Benzopiranos/antagonistas & inibidores , Benzopiranos/química , Benzopiranos/metabolismo , Benzopiranos/toxicidade , Biotransformação , Catarata/metabolismo , Catarata/patologia , Glutationa/metabolismo , Cristalino/efeitos dos fármacos , Inibidores de Lipoxigenase , Masculino , Técnicas de Cultura de Órgãos , Ratos , Ratos Sprague-Dawley , Tiazóis/antagonistas & inibidores , Tiazóis/química , Tiazóis/metabolismo , Tiazóis/toxicidade , Xenobióticos/antagonistas & inibidores , Xenobióticos/química , Xenobióticos/metabolismo , Xenobióticos/toxicidadeRESUMO
Levonantradol exhibits potent analgetic activity in standard animal tests and appears not to act directly at opiate receptors. It is currently in clinical trials as an analgesic and antiemetic. The pharmacokinetic behavior of levonantradol, administered orally or intramuscularly, has been investigated in man at dose levels of 0.25 to 3.0 mg and in animals at 0.03 to 10 mg/kg, using a specific HPLC/electrochemical assay. Only desacetyllevonantradol is detected in plasma, due to rapid in vivo deacetylation of levonantradol. In man, at the various doses tested, plasma concentrations of desacetyllevonantradol range from less than 5 to 51 ng/ml. Comparable plasma levels and clinical activity occur at nearly identical doses after oral and intramuscular dosing, suggesting good oral absorption in man. In animals, desacetyllevonantradol has a time of peak concentration of 1 to 2 hours and an elimination half-life of 1 to 2 hours. In animals, a tenfold higher oral dose is needed to achieve the same plasma drug levels as that after an intramuscular dose, suggesting extensive first-pass metabolism following oral administration. Little or no evidence for drug accumulation and sex differences in plasma concentrations of desacetyllevonantradol is noted during chronic intramuscular dosing in laboratory animals.
Assuntos
Fenantridinas/metabolismo , Adolescente , Adulto , Animais , Biotransformação , Cães , Feminino , Humanos , Cinética , Macaca fascicularis , Masculino , Pessoa de Meia-Idade , Fenantridinas/administração & dosagem , Ratos , Ratos Endogâmicos , Especificidade da Espécie , EstereoisomerismoAssuntos
Imunossupressores/química , Lactonas/química , Ramnose/química , Tacrolimo/análogos & derivados , Administração Oral , Animais , Sequência de Carboidratos , Humanos , Imunossupressores/administração & dosagem , Imunossupressores/farmacologia , Dados de Sequência Molecular , Ratos , Tacrolimo/administração & dosagem , Tacrolimo/química , Tacrolimo/farmacologiaAssuntos
Bebidas Alcoólicas , Etanol , Transtornos Relacionados ao Uso de Substâncias , Consumo de Bebidas Alcoólicas , Alcoolismo , Cerveja , Sistema Nervoso Central/efeitos dos fármacos , Sistema Digestório/efeitos dos fármacos , Tolerância a Medicamentos , Etanol/efeitos adversos , Etanol/farmacologia , Etanol/toxicidade , Humanos , Rim/efeitos dos fármacos , Fígado/efeitos dos fármacos , Comportamento Sexual , VinhoRESUMO
After intravenous or oral administration to rats and dogs, azithromycin was rapidly distributed into the tissues, where concentrations frequently exceeded those in serum by 100-fold or more within 24 h of a single dose. Tissue concentrations were proportional to the dose following single administrations of 10 to 40 mg/kg in rats and dogs. Tissue concentrations were higher after multiple dosing and became greater as the dose was increased from 10 to 40 mg/kg. Elimination half-lives were similar in most tissues and were about 40 h in rats after seven doses of 20 mg/kg and about 90 h in dogs after five doses of 30 mg/kg. Serum concentrations declined in a multi-exponential manner, reflecting initial rapid distribution into tissues and then slow return to serum from tissues. Azithromycin had good oral bioavailability in rats and dogs (46% and 97%, respectively). Rapid uptake of azithromycin by tissues from serum and slow redistribution from tissues to serum are apparently factors governing the pharmacokinetics of azithromycin in rats and dogs. Serum concentrations do not reflect the availability of azithromycin in tissues.
Assuntos
Eritromicina/análogos & derivados , Administração Oral , Animais , Azitromicina , Disponibilidade Biológica , Cães , Eritromicina/administração & dosagem , Eritromicina/sangue , Eritromicina/farmacocinética , Meia-Vida , Infusões Intravenosas , Ratos , Distribuição TecidualRESUMO
High-pressure liquid chromatography with electrochemical detection permits sensitive, selective and quantitative analysis of biological and pharmaceutical compounds containing electroactive functional groups. In support of pharmacological and clinical studies with nantradol, a potent, nonopioid analgetic, a specific HPLC/electrochemical assay for nantradol and related compounds in plasma was recently developed. In preliminary studies we have now extended this technique to the detection of delta 9- and 11-OH-delta 9- tetrahydrocannabinol. Results are presented which indicate that HPLC coupled to an electrochemical detector provides sensitivity for these compounds in plasma in the low ng/ml range.
Assuntos
Dronabinol/sangue , Fenantridinas/sangue , Cromatografia Líquida de Alta Pressão/métodos , Eletroquímica/métodos , HumanosRESUMO
The macrolide antibiotics azithromycin, roxithromycin and spiramycin were examined in parallel for in vivo activity against Toxoplasma gondii. Azithromycin was considerably more active in protecting mice against death due to acute toxoplasmosis even when the other two antibiotics were used at twice its dose. The higher activity of azithromycin prompted a further examination of its activity against five different strains of Toxoplasma gondii, including two isolated from patients with AIDS. Although variable degrees of protection against death were noted, treatment with 200 mg/kg/day for ten days was sufficient to promote survival of 100% of mice infected with inocula as high as 1 x 10(5) tachyzoites of Toxoplasma gondii. 90% of mice inoculated with 1 x 10(5) tachyzoites of strain MO, isolated from an AIDS patient, and treated orally with 200 mg/kg/day for ten days survived the infection whereas only 40% of mice infected with the same inoculum of the SOU strain, also isolated from an AIDS patient, survived. Tissue concentrations of azithromycin were examined in treated infected and non-infected mice. In both groups of mice azithromycin attained high concentrations in liver, spleen and heart, which exceeded concurrent serum levels by 25- to 200-fold. The concentrations in the brain were almost tenfold higher than the concentrations in serum after treatment with 200 mg/kg/day for ten days. Moreover, the concentrations in brains of infected mice were approximately two-fold higher than in brains of non-infected mice.
Assuntos
Eritromicina/análogos & derivados , Roxitromicina/uso terapêutico , Espiramicina/uso terapêutico , Toxoplasma/efeitos dos fármacos , Toxoplasmose Animal/tratamento farmacológico , Animais , Azitromicina , Modelos Animais de Doenças , Avaliação Pré-Clínica de Medicamentos , Eritromicina/farmacocinética , Eritromicina/farmacologia , Eritromicina/uso terapêutico , Feminino , Camundongos , Roxitromicina/farmacologia , Espiramicina/farmacologia , Distribuição TecidualRESUMO
The pharmacokinetics of azithromycin, a new azalide antibiotic, were examined in man. Approximately 37% of a single oral dose of 500 mg was bioavailable and produced a peak serum concentration of 0.4 mg/l. Multiple dose regimens (two doses of 500 mg separated by 12 h and followed by 500 mg qds for five days, or two doses of 250 mg separated by 12 h and followed by 250 mg qds for nine days) produced only slight increases in peak serum concentrations. The serum protein binding of azithromycin declined from about 50% at 0.02 mg/l to 12% at 0.5 mg/l. Tissue concentrations of azithromycin were much higher than serum concentrations. After two 250 mg doses 12 h apart, peak azithromycin concentrations exceeded 3 mg/kg in prostate, tonsil and many other tissues. Concentrations in tissues declined with apparent half-lives of 2.3 days in prostate and 3.2 days in tonsil. The high tissue concentrations suggest that proposed standard dosage regimens of 500 mg qds on day 1 followed by 250 mg qds for four days, or three daily dosages of 500 mg, will produce tissue concentrations above 3 mg/kg in a variety of tissues. Since these tissue concentrations exceed the MICs of relevant pathogens, these dosage regimens should be effective against respiratory tract and soft-tissue infections. A single 1 g dose may be effective in the treatment of many sexually transmitted diseases.
Assuntos
Eritromicina/análogos & derivados , Adolescente , Adulto , Azitromicina , Disponibilidade Biológica , Eritromicina/sangue , Eritromicina/farmacocinética , Meia-Vida , Humanos , Análise dos Mínimos Quadrados , Masculino , Pessoa de Meia-Idade , Distribuição TecidualRESUMO
High-performance liquid chromatographic methods using reversed-phase chromatography and electrochemical detection have been developed for the quantitation of azithromycin in serum and tissues of laboratory animals and humans. Serum sample preparation involved addition of internal standard, alkalinization, and solvent extraction. Tissue sample preparation involved Polytron homogenization in acetonitrile containing internal standard, evaporation of the supernatant, alkalinization of the residue, and solvent extraction. Serum samples were chromatographed on an alkylphenyl-bonded silica column eluted with pH 6.8-7.2 mobile phase with a dual-electrode coulometric detector operated in the oxidative screen mode. Serum and tissue samples were chromatographed on a gamma RP-1 alumina column with pH 11 mobile phase with a glassy carbon amperometric detector. Recovery of azithromycin was 87% from serum and 85% from tissues. Linear standard curves were prepared in serum over two concentration ranges (0.01-0.20 and 0.20-2.0 micrograms/ml) and in tissues over several concentration ranges (0.1-2, 1-10, 10-100, and 100-1000 micrograms/g). In serum and tissues, intra- and inter-assay precision ranged from 1 to 8% and 4 to 11%, respectively. The tissue assay has been applied to liver, kidney, lung, spleen, muscle, fat, brain, tonsil, lymph nodes, eye, prostate and other urological tissues, and gynecological tissues.
Assuntos
Cromatografia Líquida de Alta Pressão/métodos , Eritromicina/análogos & derivados , Azitromicina , Química Encefálica , Eletroquímica , Eritromicina/análise , Eritromicina/sangue , Humanos , Rim/química , Fígado/química , Músculos/químicaRESUMO
Patients scheduled to undergo tonsillectomy were administered 500 mg oral azithromycin as two 250 mg capsules given 12 h apart. Between 9 h and one week after the second dose, tonsil samples were taken during surgery and assayed for azithromycin. Mean concentrations in tonsillar tissue, 12 and 24 h after the second of the two 250 mg doses given 12 h apart, were 4.5 and 3.9 micrograms/g, respectively. Concurrent mean serum concentrations were approximately 0.03 and 0.01 micrograms/g, respectively. The mean concentration in tonsillar tissue 7.5 days after the last dose was 0.93 micrograms/g. The apparent half-life of drug in the tissue was 76 h. The ratio of mean concentration in tissue to that in serum was greater than 150-fold for all time intervals. The presence of high azithromycin concentrations in tonsillar tissue suggests that a once-daily regimen over five days or less may be effective in treating tonsillo-pharyngitis.
Assuntos
Eritromicina/análogos & derivados , Tonsila Palatina/química , Administração Oral , Adulto , Azitromicina , Cápsulas , Doença Crônica , Esquema de Medicação , Eritromicina/administração & dosagem , Eritromicina/análise , Eritromicina/farmacocinética , Meia-Vida , Humanos , Masculino , Tonsila Palatina/metabolismo , Fatores de Tempo , Tonsilite/metabolismoRESUMO
A multiple assay capable of reliably determining vitamins D(2) and D(3) (ergocalciferol and cholecalciferol), 25(OH)D(2) (25-hydroxyvitamin D(2)) and 25(OH)D(3) (25-hydroxyvitamin D(3)), 24,25(OH)(2)D (24,25-dihydroxyvitamin D), 25,26(OH)(2)D (25,26-dihydroxyvitamin D) and 1,25(OH)(2)D (1,25-dihydroxyvitamin D) in a single 3-5ml sample of human plasma was developed. The procedure involves methanol/methylene chloride extraction of plasma lipids followed by separation of the metabolites and purification from interfering contaminants by batch elution chromatography on Sephadex LH-20 and Lipidex 5000 and by h.p.l.c. (high-pressure liquid chromatography). Vitamins D(2) and D(3) and 25(OH)D(2) and 25(OH)D(3) are quantified by h.p.l.c. by using u.v. detection, comparing their peak heights with those of standards. 24,25(OH)(2)D and 25,26(OH)(2)D are measured by competitive protein-binding assay with diluted plasma from vitamin D-deficient rats. 1,25(OH)(2)D is measured by competitive protein-binding assay with diluted cytosol from vitamin D-deficient chick intestine. Values in normal human plasma samples taken in February are: vitamin D 3.5+/-2.5ng/ml; 25(OH)D 31.6+/-9.3ng/ml; 24,25(OH)(2)D 3.5+/-1.4ng/ml; 25,26(OH)(2)D 0.7+/-0.5ng/ml; 1,25(OH)(2)D 31+/-9pg/ml (means+/-s.d.). Values in two normal human plasma samples taken in February after 1 week of high sun exposure are: vitamin D 27.1+/-7.9ng/ml; 25(OH)D 56.8+/-4.2ng/ml; 24,25(OH)(2)D 4.3+/-1.6ng/ml; 25,26(OH)(2)D 0.5+/-0.2ng/ml. Values in anephric-human plasma are: vitamin D 2.7+/-0.8ng/ml; 25(OH)D 36.4+/-16.5ng/ml; 24,25(OH)(2)D 1.9+/-1.3ng/ml; 25,26(OH)(2)D 0.6+/-0.3ng/ml; 1,25(OH)(2)D was undetectable.
Assuntos
Nefrectomia , Vitamina D/sangue , Animais , Galinhas , Colecalciferol/sangue , Cromatografia Líquida de Alta Pressão , Cromatografia por Troca Iônica , Di-Hidroxicolecalciferóis/sangue , Ergocalciferóis/sangue , Humanos , Hidroxicolecalciferóis/sangue , Masculino , Métodos , Ensaio Radioligante , RatosRESUMO
A major vitamin D metabolite was isolated in pure form from the blood plasma of chicks either maintenance levels or large doses of vitamin D3. The isolation involved methanol-chloroform extraction and five column chromatographic procedures. The metabolite purification and elution position on these columns were followed by a competitive protein binding assay. The metabolite was identified, using high- and low-resolution mass spectrometry, 270-MHz proton nuclear magnetic resonance spectrometry, ultraviolet absorption spectrophotometry, Fourier transform infrared spectrophotometry, and specific chemical reactions, as 3 beta,-25-dihydroxy-9,10-seco-5,7,10(19)-cholestatrieno-26,23-lactone. The trivial names 25-hydroxyvitamin D3 26,23-lactone or calcidiol 26,23-lactone are suggested for this compound.